Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: A retrospective analysis

British Journal of Dermatology

Volumn 171, Issue 5, 2014, Pages 1181-1188

  Chiu, H Y ^a,b   Wang, T S ^b   Chan, C C ^a,b   Cheng, Y P ^b   Lin, S J ^a,b,c   Tsai, T F ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; EFALIZUMAB; ETANERCEPT; HLA ANTIGEN; HLA CW6 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 23; UNCLASSIFIED DRUG; USTEKINUMAB; BIOLOGICAL MARKER; DERMATOLOGICAL AGENT; HLA C ANTIGEN; HLA-C*06 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; ALLELE; ARTICLE; BODY MASS; BODY WEIGHT; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CHINA; ETHNOLOGY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; CHINA; DERMATOLOGIC AGENTS; FEMALE; HLA-C ANTIGENS; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PSORIASIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84911448762     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13056     Document Type: Article

References (37)

1. Laws PM, Downs AM, Parslew R, et al,. Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. Br J Dermatol 2012; 166: 189-95.
2. Kimball AB, Gordon KB, Fakharzadeh S, et al,. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012; 166: 861-72.
3. Lebwohl M, Papp K, Han C, et al,. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010; 162: 137-46.
4. Chiu H-Y, Cheng Y-P, Tsai T-F,. T helper type 17 in psoriasis: from basic immunology to clinical practice. Dermatol Sin 2012; 30: 136-41.
5. Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
6. Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
7. Tsai TF, Chiu HY, Song M, Chan D,. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. Br J Dermatol 2013; 168: 444-6.
8. ®-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol 2011; 164: 553-9.
9. Chiu HY, Chen CH, Wu MS, et al,. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol 2013; 169: 1295-303.
10. Tsai TF, Ho V, Song M, et al,. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol 2012; 167: 1145-52.
11. Talamonti M, Botti E, Galluzzo M, et al,. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol 2013; 169: 458-63.
12. Prieto-Perez R, Cabaleiro T, Daudén E, et al,. Genetics of psoriasis and pharmacogenetics of biological drugs. Autoimmune Dis 2013; 2013: 613086.
13. Chiu HY, Huang PY, Jee SH, et al,. HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis. Br J Dermatol 2012; 166: 288-97.
14. Gudjõnsson JE, Kárason A, Antonsdõttir AA, et al,. HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol 2002; 118: 362-5.
15. Tsai TF, Hu CY, Tsai WL, et al,. HLA-Cw6 specificity and polymorphic residues are associated with susceptibility among Chinese psoriatics in Taiwan. Arch Dermatol Res 2002; 294: 214-20.
16. Hebert HL, Ali FR, Bowes J, et al,. Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br J Dermatol 2012; 166: 474-82.
17. Julià M, Guilabert A, Lozano F, et al,. The role of Fcγ receptor polymorphisms in the response to anti-tumor necrosis factor therapy in psoriasis: a pharmacogenetic study. JAMA Dermatol 2013; 149: 1033-9.
18. Gedebjerg A, Johansen C, Kragballe K, Iversen L,. IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab. Acta Derm Venereol 2013; 93: 150-5.
19. Tejasvi T, Stuart PE, Chandran V, et al,. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 2012; 132: 593-600.
20. Vasilopoulos Y, Manolika M, Zafiriou E, et al,. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol Diagn Ther 2012; 16: 29-34.
21. Elder JT, Bruce AT, Gudjonsson JE, et al,. Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol 2010; 130: 1213-26.
22. Russell TJ, Schultes LM, Kuban DJ,. Histocompatibility (HL-A) antigens associated with psoriasis. N Engl J Med 1972; 287: 738-40.
23. Fan X, Yang S, Sun LD, et al,. Comparison of clinical features of HLA-Cw 0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol 2007; 87: 335-40.
24. Chang YT, Tsai SF, Lee DD, et al,. A study of candidate genes for psoriasis near HLA-C in Chinese patients with psoriasis. Br J Dermatol 2003; 148: 418-23.
25. Fan X, Yang S, Huang W, et al,. Fine mapping of the psoriasis susceptibility locus PSORS1 supports HLA-C as the susceptibility gene in the Han Chinese population. PLoS Genet 2008; 4: e1000038.
26. Nair RP, Ding J, Callis DK, et al,. Psoriasis bench to bedside: genetics meets immunology. Arch Dermatol 2009; 145: 462-4.
27. + T cells. Clin Exp Immunol 2004; 138: 83-93.
28. Elder JT,. PSORS1: linking genetics and immunology. J Invest Dermatol 2006; 126: 1205-6.
29. Liao YH, Jee SH, Sheu BC, et al,. Increased expression of the natural killer cell inhibitory receptor CD94/NKG2A and CD158b on circulating and lesional T cells in patients with chronic plaque psoriasis. Br J Dermatol 2006; 155: 318-24.
30. Gudjonsson JE, Karason A, Runarsdottir EH, et al,. Distinct clinical differences between HLA-Cw 0602 positive and negative psoriasis patients-an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 2006; 126: 740-5.
31. Halilova KI, Brown EE, Morgan SL, et al,. Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int J Rheumatol 2012; 2012: 978396.
32. Mori S, Hirose J, Yonemura K,. Contribution of HLA-DRB1 04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis. Clin Rheumatol 2010; 29: 1357-66.
33. Ryan C, Menter A, Warren RB,. The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. Mol Diagn Ther 2010; 14: 81-93.
34. Lebwohl M, Yeilding N, Szapary P, et al,. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 2010; 63: 571-9.
35. Zhu Y, Hu C, Lu M, et al,. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 2009; 49: 162-75.
36. Res PC, Piskin G, de Boer OJ, et al,. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS ONE 2010; 5: e14108.
37. + T cells. J Immunol 2009; 182: 5296-305.